Quantcast
Last updated on April 17, 2014 at 8:59 EDT

Latest Quinazolines Stories

2006-06-05 07:40:00

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose Baselga,...

2006-06-03 14:18:49

By Lisa Richwine ATLANTA (Reuters) - An experimental drug added to chemotherapy slowed aggressive, late-stage breast cancers that resumed growing despite standard treatment with the drug Herceptin, U.S. researchers said on Saturday. The drug, Tykerb, by GlaxoSmithKline Plc, also showed potential to help some patients with advanced kidney cancer, another study showed. Glaxo hopes to begin selling the drug next year, but must await regulatory approval. Industry analysts predict it...

2006-06-03 10:06:01

ATLANTA (Reuters) - GlaxoSmithKline's experimental pill Tykerb helped some patients with advanced kidney cancer live longer, French researchers reported on Saturday. No difference in survival was seen for the overall group of 416 patients studied, said scientists at University Hospital of Bordeaux. A benefit was seen, however, in 241 of those patients who had tumors that produced the highest amounts of a protein called EGFR, which helps tumor cells grow and divide. Patients in that...

2006-06-01 15:29:13

WASHINGTON (Reuters) - Adding a prescription arthritis drug to a targeted cancer therapy triples the number of lung cancer patients who are helped, U.S. researchers said on Thursday. Pfizer's anti-inflammatory drug Celebrex, given along with OSI Pharmaceuticals Inc.'s Tarceva, increased response rates in lung cancer patients from about 10 percent to 33 percent, reported the researchers at the University of California, Los Angeles. The study, published in the journal Clinical Cancer...

2005-11-30 09:47:24

LONDON (Reuters) - GlaxoSmithKline Plc said on Wednesday it expected to have four key cancer drugs in final-stage clinical trials next year. Europe's biggest drug maker said Tykerb, formerly known as lapatinib, eltrombopag, casopitant and pazopanib all held promise for fighting tumors and helping patients overcome the side-effects of chemotherapy. Until now, oncology has been a small area for Glaxo but the group believes new products will make it a major player in the fast-growing...

2005-10-19 07:19:29

CHICAGO (Reuters) - Genentech Inc. said on Tuesday early results from a mid-stage trial show that combining lung cancer drug Tarceva with Avastin works no better than Avastin alone in patients with advanced kidney cancer, sending shares of Tarceva partner OSI Pharmaceuticals Inc. down 7 percent. As a result, the world's No. 2 biotechnology company said it will not pursue further studies of the Avastin/Tarceva combination in kidney cancer but will continue to analyze the results of...

2005-08-09 16:04:13

LOS ANGELES (August 9, 2005; 5:00 p.m., EDT) "“ By the time the human genome was mapped, cancer researchers had already begun investigating the proteins that were encoded by these newly identified genes. As the molecular engines that control all functions of the body, scientists wanted to find out how proteins work to promote health, or malfunction to cause disease. Subsequently, their discoveries have led to the development of a whole new arsenal of therapies designed to target...

2005-07-13 14:30:00

(Toronto "“ July 13, 2005) "“ An international clinical trial led by Canadian researchers has demonstrated that a drug called erlotinib increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options. The trial, funded by the Canadian Cancer Society and published in tomorrow's issue of The New England Journal of Medicine, involved 731 patients at centres in North and South America, Europe, Israel, New Zealand, Asia and South...

2005-06-14 23:08:48

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva). Patients with tumors that expressed high levels of epidermal growth factor receptor (EGFR) and low levels of phosphorylated PKB/Akt, an enzyme, responded better to erlotinib than patients with low levels of EGFR expression and high levels of phosphorylated PKB/Akt. The study findings appear in the...